Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Non-Current Liabilities (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $3.0 billion as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 26.75% to $3.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 billion through Dec 2025, up 26.75% year-over-year, with the annual reading at $3.0 billion for FY2025, 26.75% up from the prior year.
  • Total Non-Current Liabilities hit $3.0 billion in Q4 2025 for BridgeBio Pharma, up from $2.9 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $3.0 billion in Q4 2025 to a low of $1.5 billion in Q1 2021.
  • Historically, Total Non-Current Liabilities has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2021.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 216.68% in 2021 and later dropped 0.81% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $1.9 billion in 2021, then fell by 0.81% to $1.8 billion in 2022, then grew by 2.28% to $1.9 billion in 2023, then increased by 26.2% to $2.4 billion in 2024, then increased by 26.75% to $3.0 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for BBIO at $3.0 billion in Q4 2025, $2.9 billion in Q3 2025, and $2.9 billion in Q2 2025.